Anti-nuclear antibody (ANA) test is used for detecting antinuclear antibodies in blood. The immune system can make antibodies to fight with various infections. Sometimes, ANA in a body can attack the tissues in that body itself. ANA tests can help doctors to determine autoimmune ailments. A new report on the global anti-nuclear antibody testing market share, published by Market Research Future (MRFR), estimates that this market could rise at 9.6% CAGR during the forecast period. In terms of value, the market can be worth USD 1300.6 Mn by the end of the forecast period.
The primary market driver for the global anti-nuclear antibody testing market growth is increasing technological advancement. Adoption of new medical techniques and increasing prevalence of many autoimmune diseases also drive the global anti-nuclear antibody (ANA) testing market growth. The increasing use of technology in medical sector is also boosting the anti-nuclear antibody (ANA) testing market. Major brands are investing money in research development (RD) to develop more advanced medical devices or equipment for the market that can elevate the anti-nuclear antibody (ANA) testing market revenue.
The global blood tests antinuclear antibodies segmentation encompasses application, end-user, and type. MRFR’s take on the market surveys various facets of the market in-depth.
The application-based segmentation of this anti-nuclear antibody (ANA) testing market covers lupus, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and others. The lupus segment has been sub-segmented into discoid lupus erythematosus, neonatal lupus, subacute cutaneous lupus erythematosus, and systemic lupus erythematosus (SLE). The rheumatoid arthritis segment has been sub-segmented into seropositive and seronegative. The scleroderma segment has been sub-segmented into localized scleroderma and systemic scleroderma. The Sjögren's syndrome has been sub-segmented into primary and secondary.
By type, the anti-nuclear antibody (ANA) testing market has been segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence, and others. The ELISA segment has been sub-segmented into competition/inhibition ELISA, direct ELISA, indirect ELISA, and sandwich ELISA. The immunofluorescence segment has been sub-segmented into primary (direct) and secondary (indirect).
In the context of end-user, the market has been segmented into hospitals clinics, research laboratories, and others.
A geographical outlining of the global anti-nuclear antibody (ANA) testing market covers the Americas (North America South America), Europe, Asia Pacific, and the Middle East Africa (MEA).
The Americas is the largest regional market as North America alone holds the potential of being the largest regional market. Due to technological advancement and the presence of key market players, North America is a greater market than South America. The main reason for North America being the top regional market is the availability of advanced medical facilities and high disposable income of patients. USA and Canada generate the maximum revenue in the market.
Europe is the second-largest regional market due to the availability of funds for RD activities, availability of advanced medical facilities, high density of population, technological advancement, and presence of some key market players. The most powerful country-specific markets in Western Europe are France, Germany, Italy, Spain, and the UK.
During the forecast period, the Asia Pacific region can be fastest growing regional market due to high density of population, rapid development in technology, improving healthcare sector, and a large number of people suffering from different ailments that require treatment via ANA. The remarkable country-specific markets in this region are Australia, China, India, Japan, and South Korea.
The MEA is the smallest regional market due to limited development in the medical sector. Some country-specific markets that are better than most of the markets are Egypt, Saudi Arabia, and the UAE.
Big players in the global anti-nuclear antibody (ANA) testing market include Abcam PLC. (USA), Alere (USA), Antibodies Inc.(USA), Bio-Rad Laboratories, Inc. (USA), Erba Diagnostics (USA), Indur Services, Inc. (the USA), MBL International Corporation (USA), Merck KGaA (Germany), and Trinity Biotech (Republic of Ireland).
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071